SOURCE: SciClone Pharmaceuticals, Inc.

June 06, 2008 06:30 ET

SciClone Pharmaceuticals to Hold Annual Stockholders Meeting June 10, 2008

Annual Meeting and Corporate Presentation to Be Webcast Live

FOSTER CITY, CA--(Marketwire - June 6, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will hold its Annual Meeting of Stockholders on Tuesday, June 10, 2008 at 10:00 a.m. Pacific time. The meeting will be held at the San Mateo Marriott in San Mateo, CA. Registered stockholders are encouraged to attend. A live webcast of the stockholders meeting and corporate presentation will be available under the Investor Relations section of the Company's website at www.sciclone.com.

Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone Pharmaceuticals, will conduct the stockholders meeting and upon adjournment, give a corporate presentation. The corporate presentation and simultaneous webcast will contain forward-looking statements and may contain material information including an update on clinical events.

DATE:           Tuesday, June 10, 2008
TIME:           10:00 a.m. PT (1:00 p.m. ET)
                (please dial-in or log-on 10 minutes prior to the start of
                the presentation)
WEBCAST:        Live presentation and replay accessible at www.sciclone.com
LIVE CALL:      877-548-7901 (U.S./Canada)
                719-325-4884 (International)
REPLAY:         888-203-1112 (U.S./Canada)
                719-457-0820 (International)
                Passcode:  6189704
                (Replay available from 4:00 p.m. ET on June 10, 2008
                through 11:59 p.m. ET on July 11, 2008)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in a late-stage clinical trial for the treatment of hepatitis C, and successfully completed a phase 2 clinical trial in malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate Contact:
    Erin Murphy
    SciClone Pharmaceuticals, Inc.
    (650) 358-3437
    Email Contact